FindMyKOL
Clinical trialNCT03875313TerminatedPhase 1/PHASE2Interventional

Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors

SponsorCalithera Biosciences, IncEnrollment33CRCClear Cell Renal Cell CarcinomaColorectal CancerRCCSolid TumorTNBC - Triple-Negative Breast Cancer+1 more conditions
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a Phase 1b/2 study to determine the recommended phase 2 dose (RP2D), safety and tolerability, pharmacokinetics (PK) and clinical activity of the glutaminase inhibitor CB-839 with the poly adenosine diphosphate ribose polymerase (PARP) inhibitor talazoparib in participants with advanced/metastatic solid tumors.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

9 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • University of Alabama

    Birmingham, Alabama, United States

  • Winship Cancer Institute of Emory University

    Atlanta, Georgia, United States

  • University of Iowa

    Iowa City, Iowa, United States

  • Massachusetts General Hospital

    Boston, Massachusetts, United States

  • Columbia University

    New York, New York, United States

  • Md Anderson

    Houston, Texas, United States

  • South Texas Accelerated Research Therapeutics, Llc

    San Antonio, Texas, United States

  • Huntsman Cancer Institute

    Salt Lake City, Utah, United States

  • University of Wisconsin

    Madison, Wisconsin, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

CB-839Talazoparib →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
20 May 2019
Primary completion
29 Jul 2020
Completion
29 Jul 2020
Last update posted
17 Feb 2022
Registered enrollment
33
Registry id
NCT03875313
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.